JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Hologic Inc

Gesloten

SectorGezondheidszorg

67.97 -0.21

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

67.39

Max

68.37

Belangrijke statistieken

By Trading Economics

Inkomsten

212M

195M

Verkoop

19M

1B

K/W

Sectorgemiddelde

28.178

34.393

EPS

1.08

Winstmarge

19.037

Werknemers

7,063

EBITDA

262M

255M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.29% upside

Dividenden

By Dow Jones

Volgende Winsten

3 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

468M

15B

Vorige openingsprijs

68.18

Vorige sluitingsprijs

67.97

Nieuwssentiment

By Acuity

24%

76%

45 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Hologic Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mei 2025, 18:46 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Hologic Shares Up Following Report of Buyout Offer From TPG, Blackstone

27 mei 2025, 20:07 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mei 2025, 19:06 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 14%. -- Barrons.com

27 mei 2025, 18:26 UTC

Acquisities, Fusies, Overnames

Hologic Stock Is Surging. Why Shares of the MedTech Company Are Up 19%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Hologic Inc Prognose

Koersdoel

By TipRanks

8.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 73.7 USD  8.29%

Hoogste 87 USD

Laagste 69 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hologic Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

7

Buy

7

Hold

0

Sell

Technische score

By Trading Central

52.69 / 58.605Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

45 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.